Unknown

Dataset Information

0

Mass spectrometric quantification of plasma glycosphingolipids in human GM3 ganglioside deficiency.


ABSTRACT:

Background

Among Amish communities of North America, biallelic mutations of ST3GAL5 (c.694C > T) eliminate synthesis of GM3 and its derivative downstream a- and b-series gangliosides. Systemic ganglioside deficiency is associated with infantile onset psychomotor retardation, slow brain growth, intractable epilepsy, deafness, and cortical visual impairment. We developed a robust quantitative assay to simultaneously characterize glycan and ceramide moieties of plasma glycosphingolipids (GSLs) among ST3GAL5 c.694C > T homozygotes (n = 8), their heterozygous siblings (n = 24), and wild type control (n = 19) individuals.

Methods

Following extraction and saponification of total plasma lipids, GSLs were purified on a tC18 cartridge column, permethylated, and subjected to nanospray ionization mass spectrometry utilizing neutral loss scanning and data-dependent acquisition. Plasma GSLs were quantified against appropriate synthetic standards.

Results

Our method demonstrated linearity from 5 to 250 μl of plasma. Recovery of synthetic GSLs spiked into plasma was 99-104% with no matrix interference. Quantitative plasma GSL profiles discriminated among ST3GAL5 genotypes: GM3 and GD3 were undetectable in ST3GAL5 c.694C > T homozygotes, who had markedly elevated lactosylceramide (19.17 ± 4.20 nmol/ml) relative to heterozygous siblings (9.62 ± 2.46 nmol/ml) and wild type controls (6.55 ± 2.16 nmol/ml). Children with systemic ganglioside deficiency had a distinctive shift in ceramide composition toward higher mass species.

Conclusions

Our quantitative glycolipidomics method discriminates among ST3GAL5 c.694C > T genotypes, can reveal subtle structural heterogeneity, and represents a useful new strategy to diagnose and monitor GSL disorders in humans.

SUBMITTER: Aoki K 

PROVIDER: S-EPMC8669435 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mass spectrometric quantification of plasma glycosphingolipids in human GM3 ganglioside deficiency.

Aoki Kazuhiro K   Heaps Adam D AD   Strauss Kevin A KA   Tiemeyer Michael M  

Clinical mass spectrometry (Del Mar, Calif.) 20190316


<h4>Background</h4>Among Amish communities of North America, biallelic mutations of <i>ST3GAL5</i> (c.694C > T) eliminate synthesis of GM3 and its derivative downstream a- and b-series gangliosides. Systemic ganglioside deficiency is associated with infantile onset psychomotor retardation, slow brain growth, intractable epilepsy, deafness, and cortical visual impairment. We developed a robust quantitative assay to simultaneously characterize glycan and ceramide moieties of plasma glycosphingolip  ...[more]

Similar Datasets

| S-EPMC6336560 | biostudies-literature
| S-EPMC10695682 | biostudies-literature
| S-EPMC3458402 | biostudies-literature
| S-EPMC2904445 | biostudies-literature
| S-EPMC152312 | biostudies-literature
| S-EPMC10275761 | biostudies-literature
| S-EPMC5228624 | biostudies-literature
| S-EPMC10869436 | biostudies-literature
| S-EPMC7996953 | biostudies-literature
| S-EPMC6513854 | biostudies-literature